clinical development raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
The public inquiry into the 2017 Manchester Arena bombing finds that MI5 missed a significant chance to take action that might have stopped the attack when they failed to obtain intelligence that would have led them to follow Salman Abedi to the car where he was storing explosives. Ken McCallum, the director-general of MI5, says he regrets that the intelligence was missed. 3 March COVID-19 in the UK: Lockdown Files: The latest leaked WhatsApp messages published by the Daily Telegraph are reported as appearing to show former Health Secretary Matt Hancock and Cabinet Secretary Simon Case joking about locking people in quarantine hotels. Office for National Statistics data for the week up to 21 February indicates that COVID-19 infections were increasing in England and Wales, but decreasing in Northern Ireland, while the situation in Scotland was uncertain. In England, the number of people testing positive for COVID-19 was estimated to be 1,298,600 (roughly 2.31% of the population around 1 in 45). The Commons Select Committee of Privileges finds that former prime minister Boris Johnson may have misled Parliament over the Partygate scandal after evidence suggested breaches of COVID-19 rules would have been "obvious" to him. In response Johnson says that none of the evidence shows he "knowingly" misled parliament, and that "it is clear from this report that I have not committed any contempt of parliament". Buckingham Palace announces the first state visit to be made by Charles III and Camilla as King and Queen Consort; they will travel to France and Germany from 26 to 31 March.
Examples of controlled processes are self-limiting growth solution, self-limited chemical vapor deposition, shaped pulse femtosecond laser techniques, plant and microbial approaches and molecular beam epitaxy.
=== EC 1.3.99 With unknown physiological acceptors === EC 1.3.99.1: The activity is included in EC 1.3.5.1, succinate dehydrogenase (quinone) EC 1.3.99.2: Now EC 1.3.8.1, butyryl-CoA dehydrogenase. EC 1.3.99.3: now EC 1.3.8.7, medium-chain acyl-CoA dehydrogenase, EC 1.3.8.8, long-chain acyl-CoA dehydrogenase and EC 1.3.8.9, very-long-chain acyl-CoA dehydrogenase EC 1.3.99.4: 3-oxosteroid 1-dehydrogenase EC 1.3.99.5: 3-oxo-5α-steroid 4-dehydrogenase (acceptor) EC 1.3.99.6: 3-oxo-5β-steroid 4-dehydrogenase EC 1.3.99.7: Now EC 1.3.8.6, glutaryl-CoA dehydrogenase EC 1.3.99.8: 2-furoyl-CoA dehydrogenase EC 1.3.99.9: Now EC 1.21.99.1, β-cyclopiazonate dehydrogenase EC 1.3.99.10: Now EC 1.3.8.4, isovaleryl-CoA dehydrogenase EC 1.3.99.11: transferred to EC 1.3.5.2, dihydroorotate dehydrogenase EC 1.3.99.12: Now classified as EC 1.3.8.5, 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.99.13: Now EC 1.3.8.8, long-chain-acyl-CoA dehydrogenase EC 1.3.99.14: cyclohexanone dehydrogenase EC 1.3.99.15: Now EC 1.3.7.8 EC 1.3.99.16: isoquinoline 1-oxidoreductase EC 1.3.99.17: quinoline 2-oxidoreductase EC 1.3.99.18: quinaldate 4-oxidoreductase EC 1.3.99.19: quinoline-4-carboxylate 2-oxidoreductase EC 1.3.99.20: Now EC 1.3.7.9, 4-hydroxybenzoyl-CoA reductase EC 1.3.99.21: Now EC 1.3.8.3, (R)-benzylsuccinyl-CoA dehydrogenase EC 1.3.99.22: Now EC 1.3.98.3, coproporphyrinogen dehydrogenase EC 1.3.99.23: all-trans-retinol 13,14-reductase EC 1.3.99.24: Now EC 1.3.8.16, 2-amino-4-deoxychorismate dehydrogenase EC 1.3.99.25: carvone reductase EC 1.3.99.26: all-trans-ζ-carotene desaturase EC 1.3.99.27: 1-hydroxycarotenoid 3,4-desaturase EC 1.3.99.28: phytoene desaturase (neurosporene-forming) EC 1.3.99.29: phytoene desaturase (zeta-carotene-forming) EC 1.3.99.30: phytoene desaturase (3,4-didehydrolycopene-forming) EC 1.3.99.31: phytoene desaturase (lycopene-forming) EC 1.3.99.32: glutaryl-CoA dehydrogenase (non-decarboxylating) EC 1.3.99.33: urocanate reductase EC 1.3.99.34: Now classified as EC 1.3.7.11, 2,3-bis-O-geranylgeranyl-sn-glycero-phospholipid reductase EC 1.3.99.35: Now EC 1.3.7.15, chlorophyllide a reductase * EC 1.3.99.36: cypemycin cysteine dehydrogenase (decarboxylating) EC 1.3.99.37: 1-hydroxy-2-isopentenylcarotenoid 3,4-desaturase EC 1.3.99.38: menaquinone-9 β-reductase EC 1.3.99.39: carotenoid φ-ring synthase EC 1.3.99.40: carotenoid χ-ring synthase
== Importance in nuclear reactors == If a nuclear reactor happened to be prompt critical – even very slightly – the number of neutrons would increase exponentially at a high rate, and very quickly the reactor would become uncontrollable by means of external mechanisms. The control of the power rise would then be left to its intrinsic physical stability factors, like the thermal dilatation of the core, or the increased resonance absorptions of neutrons, that usually tend to decrease the reactor's reactivity when temperature rises; but the reactor would run the risk of being damaged or destroyed by heat. However, thanks to the delayed neutrons, it is possible to leave the reactor in a subcritical state as far as only prompt neutrons are concerned: the delayed neutrons come a moment later, just in time to sustain the chain reaction when it is going to die out. In that regime, neutron production overall still grows exponentially, but on a time scale that is governed by the delayed neutron production, which is slow enough to be controlled (just as an otherwise unstable bicycle can be balanced because human reflexes are quick enough on the time scale of its instability). For example, with a neutron lifetime of 10−3 s and a reactivity step of 0.0022, the reactor period would be 0.45 s without delayed neutrons, but is 14 s with them. Thus, by widening the margins of non-operation and supercriticality and allowing more time to regulate the reactor, the delayed neutrons are essential to inherent reactor safety, even in reactors requiring active control.
Sources: en.wikipedia.org
Its all too easy to make a film that exists solely for the purpose of setting up future installments and expanding a world, rather than a film that stands on its own merits while deftly hinting or winking at its place in the larger mythos. In that, the MCU has flourished." He felt that Iron Man "itself was aimed at being an enjoyable stand-alone experience, not as an overall advertisement for 17 subsequent movies. That mentality has persisted through most of the MCU films over the past decade, which is all the more impressive as its roster of heroes now exceeds the two-dozen mark."
== Caesium-134 == Caesium-134 has a half-life of 2.0650 years. It is produced both directly (at a very small yield because 134Xe is stable) as a fission product and via neutron capture from nonradioactive 133Cs (neutron capture cross section 29 barns), which is a common fission product. It is not produced by nuclear weapons because 133Cs is created by beta decay of original fission products long after the nuclear explosion is over. The combined yield of 133Cs and 134Cs is given as 6.7896%. The proportion between the two will change with continued neutron irradiation. 134Cs also captures neutrons with a cross section of 140 barns, becoming long-lived radioactive 135Cs. Caesium-134 undergoes beta decay (β−), producing stable 134Ba after emitting on average 2.23 gamma ray photons (mean energy 0.698 MeV).
4 On 21 December 1995, a major reshuffle took place amongst existing Ministers, mainly to discharge particular Ministers of portfolios which had proven troublesome for the government. 5 On 26 April 1996, George Cash resigned from the ministry due to ill health. Graham Kierath and Kevin Minson adopted his portfolios, whilst Norman Moore was elected leader of the Government in the Legislative Council four days later.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.